The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.


Selenium and selenoprotein P in nonalcoholic fatty liver disease.

TitleSelenium and selenoprotein P in nonalcoholic fatty liver disease.
Publication TypeJournal Article
Year of Publication2020
AuthorsPolyzos, S. A., Kountouras J., Goulas A., & Duntas L.
JournalHormones (Athens)
Date Published2020 Mar
KeywordsAnimals, Carcinoma, Hepatocellular, Dietary Supplements, Humans, Insulin Resistance, Liver Cirrhosis, Liver Neoplasms, Non-alcoholic Fatty Liver Disease, Oxidative Stress, Selenium, Selenoprotein P

Conflicting data link nonalcoholic fatty liver disease (NAFLD), a disease with no currently approved treatment, with selenium (Se) and selenoprotein P (SELENOP), a glycoprotein synthesized and primarily secreted by the hepatocytes, functioning as a Se transporter from the liver to other tissues. This review aims to summarize the evidence between Se, SELENOP, and NAFLD, which may hopefully clarify whether current data on Se and SELENOP in NAFLD warrant further investigation for their diagnostic and therapeutic potential. Most, albeit not all, experimental data show a favorable effect of Se on hepatic steatosis, inflammation, and fibrosis. It seems that Se may exert an antioxidant effect on the liver, at least partly via increasing the activity of glutathione peroxidase, whose depletion contributes to the pathogenesis of hepatic inflammation and fibrosis. Se may also affect metalloproteinases, cytokines, and growth factors participating in the pathogenesis of NAFLD and, most importantly, may induce the apoptosis of hepatic stellate cells, the key players in hepatic fibrosis. However, the association between Se or SELENOP and insulin resistance, which is a principal pathogenetic factor of NAFLD, remains inconclusive. Clinical studies on Se or SELENOP in NAFLD are conflicting, apart from those in advanced liver disease (cirrhosis or hepatocellular carcinoma), in which lower circulating Se and SELENOP are constant findings. Existing data warrant further mechanistic studies in valid animal models of human NAFLD. Prospective cohort studies and possibly randomized controlled trials are also needed to elucidate the diagnostic and therapeutic potential of Se supplementation in selected NAFLD individuals with Se deficiency.

Alternate JournalHormones (Athens)
PubMed ID31493247


Secretariat of the School of Medicine


School of Medicine's presence in social networks
Follow Us or Connect with us.